Propafenone: An effective agent for the management of supraventricular arrhythmias

Journal of Cardiovascular Electrophysiology

Volumn 7, Issue 4, 1996, Pages 353-364

  Grant, Augustus O ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

atrial fibrillation; propafenone; supraventricular tachycardia; Wolff Parkinson White syndrome

Indexed keywords

ANTIARRHYTHMIC AGENT; CIMETIDINE; CYCLOSPORIN; DEBRISOQUINE; DESIPRAMINE; DIGOXIN; DISOPYRAMIDE; DOPAMINE; DRUG METABOLITE; ENCAINIDE; FLECAINIDE; LACTATE SODIUM; LIDOCAINE; LORCAINIDE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; THEOPHYLLINE; TOCAINIDE; VERAPAMIL;

CATHETER ABLATION; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SINOATRIAL BLOCK; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REENTRY TACHYCARDIA; REVIEW; SINGLE BLIND PROCEDURE; SINUS NODE DYSFUNCTION; TACHYCARDIA; WOLFF PARKINSON WHITE SYNDROME;

EID: 0029864970     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1996.tb00537.x     Document Type: Review

References (74)

1. max of the action potential by propafenone and its voltage-, time-, and pH-dependence in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1980; 315:55-62.
2. Na blockade by antiarrhythmics. Pflügers Arch 1983;396:100-209.
3. Schreibmayer W, Linder W: Stereoselective interactions of (R)-and (S)-propafenone with the cardiac sodium channel. J Cardiovasc Pharmacol 1992;20:324-331.
4. + channels by antiarrhythmic drugs: The effect of amiodarone, propafenone and diprafenone. J Membr Biol 1988;102:105-119.
5. + channels. Circ Res 1989;64:867-881.
6. Honjo H, Watanabe T, Kamiya K, et al: Effects of propafenone on electrical and mechanical activities of single ventricular myocytes isolated from guinea-pig hearts. Br J Pharmacol 1989;97:731-738.
7. Campbell TJ: Kinetics of onset of rate-dependent effects of class 1 antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983;17:344-352.
8. Thompson KA, Iansmith DHS, Siddoway LA, et al: Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther 1988;244:950-955.
9. Koller B, Franz MR: New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart. J Cardiovasc Pharmacol 1994;24:753-760.
10. Malfatto G, Zaza A, Forster M, et al: Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther 1988;246:419-426.
11. Valenzuela C, Delgado C, Tamargo J: Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers. J Cardiovasc Pharmacol 1987;10:523-529.
12. Weirich J, Hohnloser S, Antoni H: Differential analysis of frequency-dependent effects of antiarrhythmic drugs: Importance of the saturation behavior of frequency-dependent sodium-channel blockade. J Cardiovasc Pharmacol 1991;103:1453-1457.
13. Vaughan Williams EM: Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol 1991;31:123-135.
14. 45Ca movements and contractile responses in vascular smooth muscle. Br J Pharmacol 1991;103:1453-1457.
15. Ledda F, Mantelli L, Manzini S, et al: Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 1981;3:1162-1173.
16. Delgado C, Tamargo J, Henzel D, et al: Effects of propafenone on calcium current in guinea-pig ventricular cells. Br J Pharmacol 1991;102:346P.
17. Duan D, Fermini B, Nattel S: Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993;264:1113-1123.
18. Spinelli W, Hoffman BF: Mechanism of termination of reentrant atrial arrhythmias by class 1 and class 111 antiarrhythmic agents. Circ Res 1989;65:1565-1579.
19. Inoue H, Yamashita T, Nozake A, et al: Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: Role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol 1991;18:1098-1104.
20. Bryson HM, Palmer KJ, Langtry HD, et al: Propafenone - A reappraisal of its pharmacology, pharmacokinetics and therapeutic uses in cardiac arrhythmias. Drugs 1993;45:85-130.
21. Libadoni M, Piovan D, Busato E, et al: Transfer of propafenone and 5-OH propafenone to fetal plasma and maternal milk. Br J Clin Pharmacol 1991;32:527-528.
22. Lee JT, Kroemer H, Silbestein D, et al: The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990;322:1764-1768.
23. Funck-Brentano C, Droemer HK, Pavlou H, et al: Genetically-determined interaction between propafenone and low dose quinidine: Role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989; 27:435-444.
24. Sung RJ, Chong M-S, Chiang BN: Clinical electrophysiology of supraventricular tachycardia. Cardiol Clin 1983;1:225-251.
25. Pritchett ELC: Management of atrial fibrillation. N Engl J Med 1992;326:1264-1271.
26. Falk RH, Knowton AA, Bernard SA, et al: Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Intern Med 1987;106:503-506.
27. Connolly SJ, Mulji AS, Goffert DL, et al: Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after surgery. J Am Coll Cardiol 1989;10:1145-1148.
28. Funk-Brentano C, Kroemer HK, Lee JT, et al: Propafenone. N Engl J Med 1990;322:518-522.
29. Vita JA, Fiedman PL, Cantolliam C, et al: Efficacy of intravenous propafenone for the acute management of atrial fibrillation. Am J Cardiol 1989;63:1275-1278.
30. Suttorp MJ, Kingma JH, Jessurun ER, et al: The value of IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-1727.
31. Sung RJ, Tai D-Y: Electrophysiologic characteristics of accessory connections: An overview. In Benditt DG, Benson DW, eds: Cardiac Pre-excitation Syndromes. Martinus Nijhoff Publishers, Boston, 1986, pp. 165-199.
32. Giata F, Giustetto C, Riccardi R, et al: Stress and pharmacological tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. Am J Cardiol 1989;64:487-490.
33. Klein GJ, Bashore TM, Seller TD, et al: Ventricular fibrillation in the Wolff-Parkinson-White Syndrome. N Engl J Med 1979;301:1080-1085.
34. Gulamhusein S, Ko P, Klein GJ: Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome. Am Heart J 1983;106:145-147.
35. Jacob AS, Nielson DH, Gianelly RE: Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome. Ann Intern Med 1986;104:791-794.
36. Dubuc M, Kus T, Camapa MA, et al: Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White Syndrome. Am Heart J 1989;117: 370-376.
37. Boahene K, Klein GJ, Yee R, et al: Termination of acute atrial fibrillation in Wolff-Parkinson-White syndrome by procainamide and propafenone: Importance of fibrillatory cycle length. J Am Coll Cardiol 1990; 16:1408-1414.
38. Ludmer PL, McGowen NE, Antman EM, et al: Efficacy of propafenone in Wolff-Parkinson-White syndrome: Electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 1987;9:1357-1363.
39. Packer DL, Prystowsky EN: Wolff-Parkinson-White syndrome: Further progress in evaluation and treatment. In Zipes DP, Rowlands DJ, eds: Progress in Cardiology. Lea & Febiger, Philadelphia, 1988, pp. 147-187.
40. Bertini G, Conti A, Fradella G, et al: Propafenone versus amiodarone in field treatment of primary tachydysrhythmias. J Emerg Med 1990;8:15-20.
41. Bianconi L, Baccadamo R, Pappalarado A, et al: Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-338.
42. Kondili A, Kastati A, Poya Y: Comparative evaluation of verapamil, flecainide and propafenone for acute conversion of atrial fibrillation to sinus rhythm. Wien Klin Wochenschr 1990;102:510-512.
43. Goy J-J, Metrailler J-C, Humdir L, et al: Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenone. Am Heart J 1991;122:1788-1790.
44. Rostagno C, Puladini B, Pini C, et al: Feasibility of out-of-hospital treatment for supraventricular tachycardias. Am J Cardiol 1991;68:119-122.
45. Porterfield JC, Porterfield LM: Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989;63:114-116.
46. Connolly SJ, Hoffert DL: Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819.
47. Pritchett ELC, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. Ann Intern Med 1991; 114:539-544.
48. Cobbe SM: Drug therapy of supraventricular tachyarrhythmias based on efficacy or futility? Eur Heart J 1994;15:539-544.
49. Reimold SC, Cantillin CO, Friedman PL, et al: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71: 558-563.
50. Antman EM, Bearner AD, Cantillon C, et al: Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-1011.
51. Kerr CR, Klein GJ, Axles DIE, et al: Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol 1988;61:914-916.
52. Keyles AE, Murdock CJ, Yeung-Lai-Wah JA, et al: Long-term efficacy of propafenone for prevention of atrial fibrillation. Can J Cardiol 1991;7:407-409.
53. Hammill SC, Wood DL, Gersh BJ, et al: Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988; 61:473-474.
54. Coumel P, LeClerq J-F, Assayag P: European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular antiarrhythmias. Am J Cardiol 1984;54:60D-66D.
55. Huang SKS, Chenarides JG, Kuo K, et al: Propafenone for termination and prevention of atrial fibrillation - Clinical trial in 41 patients. J Am Coll Cardiol 1991; 71:130A.
56. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-757.
57. Weiner HL, McCarthy EA, Pritchett ELC: Regular ventricular rhythms in patients with symptomatic paroxysmal atrial fibrillation. J Am Coll Cardiol 1991; 17:1283-1287.
58. Rosengarten M, Brooks R: Torsade de pointes ventricular tachycardia in a hypothyroid patient tested with propafenone. Can J Cardiol 1987;3:234-239.
59. Hii JTY, Wyse G, Gillis AM, et al: Propafenone-induced torsade de pointes: Cross-reactivity with quinidine. PACE 1991;14:1568-1570.
60. Lee PK, Kerr CR, Vorderbrugge S, et al: Symptomatic sinus node dysfunction associated with the use of propafenone. Am J Cardiol 1988;62: 480-481.
61. Freedman RA, Mason JW: Invasive electrophysiology study. In Zipes DP, Rowland DJ, eds: Progress in Cardiology: Arrhythmias III. Lea & Febiger, Philadelphia, 1988, pp. 63-84.
62. Manz M, Steinbeck G, Luderitz B: Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. Am J Cardiol 1985;56:593-597.
63. Shen EN, Keung E, Huyeke E, et al: Intravenous propafenone for termination of re-entrant supraventricular tachycardia. Ann Intern Med 1986;105:655-661.
64. Hammill SC, McLanan CJ, Wood DL, et al: Double-blind study of intravenous propafenone for paroxysmal supraventricular re-entrant tachycardia. J Am Coll Cardiol 1987;9:1364-1368.
65. Singh BN, Elldrodt G, Peter CT: Verapamil: A review of its pharmacological properties and therapeutic use. Drugs 1978;15:169-197.
66. Santinelli V, De Paola M, Turco P, et al: Paroxysmal supraventricular tachycardia: Experience with propafenone. Angiology 1989;40:563-568.
67. Walafee A, Mary-Rabine L, de Rijbel R, et al: Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia. Eur Heart J 1981;2:345-352.
68. Guccione P, Drago F, Di Danata RM, et al: Oral propafenone therapy for children with arrhythmias: Efficacy and adverse effects in midterm follow-up. Am Heart J 1991;122:1022-1027.
69. Janousek J, Paul T, Reimer A, et al: Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol 1993;72:294-300.
70. Musto B, D'Onofrio A, Carallaro C, et al: Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation 1988;78:863-869.
71. Breithardt G, Borggrefe M, Weiringhaus E, et al: Effect of propafenone in the Wolff-Parkinson-White syndrome: Electrophysiologic findings and long-term follow-up. Am J Cardiol 1984;54:29D-39D.
72. Moak JP, Smith RT, Garson A: Newer antiarrhythmic drugs in children. Am Heart J 1987;113:179-185.
73. Garson A, Moak JP, Smith RT, et al: Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia. Am J Cardiol 1987; 59:1422-1424.
74. Pritchett ELC, Wilkinson WE, Clair WK, et al: Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias. Am J Cardiol 1993;72:108-110.